U.S. gives full approval to 1st COVID-19 drug for young children – National | Globalnews.ca


The U.S. drug regulator on Monday granted the primary full approval for treating COVID-19 in kids aged 28 days and older to Gilead Sciences Inc’s GILD.O drug remdesivir.

The transfer comes months after the company expanded the drug’s emergency use authorization to additionally embody kids under 12 years of age weighing a minimum of 3.5 kilograms.

The Meals and Drug Administration’s (FDA) choice makes the drug the primary permitted COVID-19 remedy for kids lower than 12 years of age, the company mentioned.

The approval is relevant to kids who’re hospitalized, or have mild-to-moderate illness and are at excessive threat of extreme COVID-19.

(Reporting by Manas Mishra in Bengaluru; Enhancing by Aditya Soni)



Leave a Comment